Psoriatic arthritis is a chronic inflammatory arthritis associated with psoriasis, causing painful, stiff, and swollen joints and related musculoskeletal symptoms. Active disease reflects ongoing inflammatory joint involvement that can progress without treatment.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Protagonist Therapeutics reported fourth quarter and full year 2025 financial results, with two NDAs submitted and multiple Phase 3 trials advancing. The company holds $646 million in cash and expects regulatory decisions in 2026.
Dr. Reddy's Laboratories has received FDA acceptance for its biosimilar application targeting Bristol-Myers Squibb's Orencia, marking the first U.S. application for an off-patent version of the arthritis treatment that generated $2.7 billion in 2025.
The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05499416 |
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis |
WITHDRAWN | PHASE4 |
| NCT04876781 |
Korean Post-marketing Surveillance for Xeljanz XR |
RECRUITING | |
| NCT04314544 |
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) |
COMPLETED | PHASE3 |
| NCT04314531 |
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03881059 |
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) |
COMPLETED | PHASE2 |
| NCT03357471 |
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease |
COMPLETED | PHASE3 |
| NCT02980692 |
Efficacy and Safety Study of SUNPG1623 |
COMPLETED | PHASE2 |
